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Safety and efficacy of intrapericardial (ipc) instillation of bleomycin (BLM) following pericardial drainage in patients with malignant
pericardial effusion (MPE) remain unclear. Patients with pathologically documented lung cancer, who had undergone pericardial
drainage for MPE within 72h of enrolment, were randomised to either arm A (observation alone after drainage) or arm B (ipc BLM at
15mg, followed by additional ipc BLM 10mg every 48h). The drainage tube was removed when daily drainage was 20ml or less. The
primary end point was survival with MPE control (effusion failure-free survival, EFFS) at 2 months. Eighty patients were enrolled, and
79 were eligible. Effusion failure-free survival at 2 months was 29% in arm A and 46% in arm B (one-sided P¼0.086 by Fisher’s exact
test). Arm B tended to favour EFFS, with a hazard ratio of 0.64 (95% confidence interval: 0.40–1.03, one-sided P¼0.030 by log-rank
test). No significant differences in the acute toxicities or complications were observed. The median survival was 79 days and 119 days
in arm A and arm B, respectively. This medium-sized trial failed to show statistical significance in the primary end point. Although ipc
BLM appeared safe and effective in the management of MPE, the therapeutic advantage seems modest.
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Malignant pericardial effusion (MPE) is a grave complication of
malignant tumours. The frequency of pericardial involvement by
malignancy has been estimated to be 10–21% at autopsy
(Theologides, 1978; Klatt and Heitz, 1990).
Malignant pericardial effusions are often asymptomatic and
detected incidentally by echocardiography or computed tomogra-
phy. Symptomatic cases, however, often manifest cardiac tampo-
nade, which can rapidly lead to cardiovascular collapse and death,
unless promptly treated (Press and Livingston, 1987).
Lung cancer is the most frequent cause of MPE, and other
common primary sites include breast cancer, oesophageal cancer,
lymphoma and leukaemia (Abraham et al, 1990; Wilkes et al, 1995;
Yonemori et al, 2007). The prognosis of MPE in lung cancer
patients is particularly poor, with a reported median survival of 3
months or less (Okamoto et al, 1993; Gornik et al, 2005).
Although prompt diagnosis and pericardial drainage result in
good palliation of symptoms, drainage alone is often inadequate to
prevent re-accumulation of the fluid after the drainage tube is
removed (Shepherd, 1997). There are numerous reports of
pericardial sclerosis for MPE by the instillation of various agents,
such as tetracycline/doxycycline (Shepherd et al, 1987; Maher et al,
1996), a streptococcal preparation (Imamura et al, 1991),
bleomycin (BLM) (Vaitkus et al, 1994; Liu et al, 1996; Maruyama
et al, 2007), thiotepa (Colleoni et al, 1998; Martinoni et al, 2004),
cisplatin/carboplatin (Moriya et al, 2000; Tomkowski et al, 2004),
5-fluorouracil (Lerner-Tung et al, 1997), anthracyclines
(Kawashima et al, 1999), vinblastine (Primrose et al, 1983),
mitoxyantrone (Norum et al, 1998), mitomycin C (Kaira et al,
2005) and
32P-colloid (Dempke and Firusian, 1999), after drainage.
Platinum agents are actually not ‘classic’ sclerosants to induce
inflammatory adhesion of the pericardial sac; they were apparently
used as local chemotherapy. Whereas each study reports favour-
able outcomes in terms of MPE control and prevention of
re-accumulation, almost all were performed as phase II trials,
and no definite conclusions could be drawn (Press and Livingston,
1987; Vaitkus et al, 1994).
In one of the very few randomised trials conducted to date, Liu
et al (1996) reported that BLM is the preferred agent for sclerosis,
because of the lower morbidity associated with it. However, to
the best of our knowledge, the efficacy and safety of pericardial
sclerosis itself has never been evaluated by a prospective
randomised trial.
This trial was aimed at evaluating the safety and efficacy of
pericardial sclerosis induced by intrapericardial (ipc) BLM
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sinstillation, as compared with pericardial drainage alone, in lung
cancer patients with MPE.
PATIENTS AND METHODS
Patient eligibility criteria
Patients with pathologically documented lung cancer, who had
undergone pericardial drainage for clinical MPE (moderate to large
accumulation of fluid), were eligible for study entry. Indications
for the drainage were clinically determined; cases after emergent
drainage and those after elective one were both included. Patient
registration should be done within 72h of drainage. The eligibility
criteria were as follows: 75 years of age or less, expected life
prognosis of 6 weeks or more with control of the MPE and
minimum organ functions (leukocyte countX3000 per mm
3,
platelet countX75000 per mm
3, haemoglobinX9.0gdl
 1 and no
renal or hepatic failure; however, laboratory abnormalities related
to cardiac tamponade were allowed). Patients with chemotherapy-
naive small cell cancer were excluded. Other exclusion criteria
included apparently non-malignant effusion (e.g., purulent effu-
sion), recurrent MPE, myocardial infarction or unstable angina
within the previous 3 months, constrictive pericarditis, active
interstitial pneumonia, severe infection and disseminated intra-
vascular coagulation. Those with an unstable clinical condition
attributable to other severe complications, such as superior vena
cava syndrome, central airway obstruction or uncontrollable
massive pleural effusion, were also excluded.
Patient eligibility was confirmed by the Japan Clinical Oncology
Group Data Center before patient registration. The study protocol
was approved by the institutional review boards at each
participating centre and all the patients provided written informed
consent.
Treatment plan
The study protocol did not limit the method used for the
pericardial drainage. Both percutaneous tube pericardiostomy
(non-surgical method), in which a drainage catheter is inserted
using the Seldinger technique, and subxiphoid pericardiostomy
(surgical method), in which a drainage tube is placed surgically,
were allowed; each participating institution, however, basically
adhered to one method, which they used in routine practice. The
drainage method used was recorded on the case report form.
After registration with telephone or facsimile, the patients were
randomly assigned to one of the two treatment arms with block
randomisation stratified by the institution. In arm A, no additional
intervention was performed and the patient was observed clinically
after the pericardial drainage. In arm B, 15mg of BLM dissolved in
20ml of normal saline was instilled through the drainage catheter
into the pericardial space immediately after the patient registra-
tion. The catheter was then clamped and reopened after 2h,
allowing resumption of the drainage. Additional doses of BLM at
10mg were instilled similarly every 48h, unless the criteria for tube
removal, as described below, were met.
The drainage tube was removed, in both arm A and arm B, when
the drainage volume per 24h was 20ml or less. If the criterion was
met during the 24h preceding randomisation in a patient allocated
to arm A, the tube was immediately removed.
Patient evaluation and follow-up
Primary control of the MPE was considered to be achieved when
the drainage tube could be successfully removed within 7 days of
randomisation. When the criterion for tube removal, that is 20ml
per 24h, could not be met by 7 days, the case was judged to show
primary failure of the protocol therapy: treatment after off-
protocol was not limited by the study protocol. When the drainage
tube had to be removed because of obstruction, but re-drainage
was clinically unnecessary, it was judged to have been successfully
removed with primary control of MPE.
Monitoring for recurrence of the MPE in those who showed
primary control was conducted by echocardiography at 1, 2, 4, 6
and 12 months. When the estimated fluid volume in the recurrent
effusion exceeded 100ml, the case was labelled as showing MPE
re-accumulation and recurrence. Re-drainage was performed as
clinically indicated.
The adverse effects of the therapy were evaluated according to
the Japan Clinical Oncology Group Toxicity Criteria (Tobinai et al,
1993), modified from the National Cancer Institute Common
Toxicity Criteria version 1.
The primary end point of the study was effusion failure-free
survival (EFFS) rate at 2 months; EFFS was patient survival without
MPE recurrence as defined above, in patients showing primary
control. It was calculated as the period from the date of pericardial
drainage to the date of MPE recurrence or the patient’s death. For
those patients with primary failure, MPE recurrence was
considered to have occurred at the date of drainage, with an EFFS
of zero. Effusion failure-free survival was judged regardless of the
other disease status.
The secondary end points included the primary MPE control
rate, time to drainage tube removal, EFFS, treatment-related
morbidity, proportion of late pericardial or cardiac complication,
overall survival (OS) and symptom scores.
Study-specific four-item symptom scores were completed by
patients at the time of randomisation (i.e., after pericardial
drainage) and at 1 month after the enrolment. The scores were
to be interviewed by the health professionals other than the
attending physicians. The items consisted of cough, pain, anorexia
and shortness of breath. The scoring was conducted as follows: as
not at all present (0), a little (1), moderate (2) and very much (3).
The score for each item and the sum of the total score for all the
four items were compared between the baseline and the follow-up
assessments, and judged to be improved (lower scores in the
follow-up assessments), stable (no change of scores) or worsened
(higher scores, or the patient could not fill out the questionnaire,
in the follow-up assessments).
Statistical considerations
From the historical data, the EFFS rate at 2 months in arm A was
assumed to be 30% and that in arm B was presumed to be 60%.
The study was designed to provide 80% power with 5% one-sided
a. The required sample size was calculated as 80 patients, 40 in
each arm, for comparing independent proportions.
The OS, time to tube removal and EFFS of both arms were
calculated by the Kaplan–Meier method and compared by log-
rank tests. The primary MPE control rate, symptom scores,
complication rates and EFFS at each of the follow-up points were
compared using Fisher’s exact test. All analyses were performed
with the SAS software version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics and treatment delivery
From August 1999 to January 2006, 80 patients from 14 institutions
were enrolled and randomised, 42 to arm A and 38 to arm B. One
patient in arm B was found to be ineligible because of late registry,
2 weeks after the pericardial drainage. All 80 patients were
analysed for their characteristics and chemotherapy morbidity,
and the 79 eligible patients were analysed for efficacy and survival.
Table 1 lists the characteristics of the patients, which were
generally well balanced between the arms, except for the
effusion cytology: there were numerically more patients with
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scytology-positive effusions in arm A. Cytology of the effusion was
positive in 58 cases out of the 76 examined (76%).
In arm B, all 38 patients received at least one ipc BLM
instillation and a total of 74 administrations: seven patients
received four administrations (total BLM dose: 45mg), five
received three administrations (total BLM: 35mg), five received
two administrations (total BLM: 25mg) and the remaining 21
received a single administration (total BLM: 15mg). There was no
apparent relationship between total dose and efficacy end points
such as EFFS, except that those required four administrations had
a worse primary control of the MPE.
A total of 24 patients (14 in arm A and 10 in arm B) received
systemic chemotherapy after drainage tube removal. Nine patients
(five in arm A and four in arm B) received gefitinib. Cytotoxic
chemotherapy was administered to 21 patients (11 in arm A and 10
in arm B).
Morbidity and early deaths
Table 2 summarises the morbidity of the protocol therapy.
Although 30 (38%) of the patients experienced some pain, no
significant difference in the incidence and severity of pain was
observed between the arms. Bleeding and infections were rare and
generally controllable. Two patients in arm B developed transient
fever of moderate degree (38–38.71C). One case with constrictive
pericarditis at 4 months and another with late cardiac dysfunction
at 12 months after the registry, both reported to be grade 2, were
observed in arm B.
As anticipated, there were as many as nine early deaths within
30 days of randomisation; five in arm A and four in arm B.
Although the death was ascribed to disease progression in the
majority, two patients in arm A died of massive bleeding during
surgical attempts at re-drainage for recurrent MPE, possibly due to
crack formation in the ventricular wall upon dissection of the
adherent pericardium. Another patient in arm B died suddenly on
day 12 of the protocol without a clear cause.
Efficacy end points
Primary control of the MPE with successful tube removal within 7
days of randomisation was achieved in 28 of the 42 cases (67%) in
arm A and 27 of the 37 eligible cases (73%) in arm B, the difference
between the two groups not being statistically significant. The
median time to tube removal was 7 days in each arm. Arm B
favoured EFFS (Figure 1), with a hazard ratio of 0.64 (95%
confidence interval: 0.40–1.03, and one-sided P¼0.030 by log-
rank test).
The EFFS at 1, 2, 4, 6 and 12 months was 50, 29, 17, 14 and 5%,
respectively, for arm A, and 65, 46, 32, 24 and 10%, respectively,
for arm B. Although arm B also favoured the primary end point,
EFFS at 2 months (46 vs 29%), the difference between the two
Table 2 Morbidity of the protocol therapy
Arm A (drainage alone) B (ipc BLM)
N 42 38
Pain
None 25 25
Medication not required 4 4
Controlled with non-opioid analgesics 9 7
Controlled with opioid analgesics 4 2
Uncontrollable 0 0
Infection
None 39 35
Controllable 3 3
Uncontrollable 0 0
Bleeding
None 42 36
Controllable 0 1
Severe 0 1
Late complications
None 42 36
Pulmonary 0 0
Cardiac function 0 1 (grade 2)
Constrictive pericarditis 0 1 (grade 2)
ipc BLM¼intrapericardial bleomycin instillation.
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Figure 1 Effusion failure-free survival (EFFS). The median EFFS was 30
days in arm A and 57 days in arm B, with a hazard ratio of 0.64 (95%
confidence interval: 0.40–1.03), with arm B significantly favouring this
parameter (one-sided P¼0.030 by log-rank test).
Table 1 Patient characteristics
Arm A (drainage alone) B (ipc BLM)
N 42 38
Gender
Male 27 24
Female 15 14
Median age (range) 60.5 (39–75) 60 (42–73)
Histology
Small cell 3 2
Non-small cell 39 36
Prior chemotherapy
Yes 29 24
No 13 14
Prior thoracic radiotherapy
Yes 11 9
No 31 29
Drainage methods
Surgical 19 17
Others 23 21
Median drainage volume in ml (range) 550 (250–1750) 600 (130–1930)
Effusion cytology
Negative 6 11
Indeterminate 1 0
Positive 33 25
Not examined 2 2
ipc BLM¼intrapericardial bleomycin instillation.
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sgroups was not statistically significant (one-sided P¼0.086 by
Fisher’s exact test).
The median OS was not significantly different between the two
arms: 79 days in arm A and 119 days in arm B. The OS rates at 6
months were 27 and 31% in arm A and arm B, respectively.
Subgroup analysis
As more patients in arm A had cytology-positive effusion, which
has been reported to be associated with a poor prognosis (Gornik
et al, 2005), subset analysis was performed according to the
effusion cytology status (Figures 2 and 3). In both cytology-positive
patients (Figure 2) and cytology-negative or -indeterminate patients
(Figure 3), arm B favoured EFFS.
Thirty-six patients had undergone surgical (subxiphoid peri-
cardiostomy) and 43 had undergone non-surgical (percutaneous
tube pericardiostomy) drainage before randomisation. Patients
with surgical drainage tended to have a longer EFFS (Figure 4). The
effect of ipc BLM was observed irrespective of the drainage method
employed; arm B tended to favour EFFS both in patients with
surgical drainage (hazard ratio 0.62, 95% confidence interval:
0.30–1.29) and in those with non-surgical drainage (hazard ratio
0.56, 95% confidence interval: 0.29–1.05).
Symptom palliation
The baseline symptom scores were taken for all of the 79 eligible
patients, at enrolment (after drainage). At the 1-month follow-up,
approximately half of the patients (55% in arm A and 51% in
arm B) had stable or improved overall scores. There were no
significant differences between the arms for any of the symptom
scores (Table 3).
DISCUSSION
Malignant pericardial effusion is a potentially life-threatening
complication of malignancy that usually manifests itself at an
advanced or terminal stage of the disease. It brings great agony to
the patient once it becomes symptomatic, with dyspnoea,
orthopnoea, chest pain and cough. Although the prognosis of the
patients with MPE is very poor, especially in those with
chemotherapy-resistant tumours such as non-small-cell lung
cancer (Press and Livingston, 1987; Okamoto et al, 1993; Gornik
et al, 2005; Yonemori et al, 2007), optimal management is very
important for palliation.
Pericardial sclerosis following drainage has been widely
performed. However, data are available mainly from phase II
trials or case series. In fact, historical comparison has failed to
demonstrate the efficacy of pericardial sclerosis over drainage
alone (Okamoto et al, 1993; Vaitkus et al, 1994). It has also been
suggested that sclerosis may be effective in preventing re-
accumulation of MPE after percutaneous tube pericardiostomy,
but not after subxiphoid pericardiotomy, because the surgical
intervention alone was considered to be sufficient to prevent
recurrent MPE (Press and Livingston, 1987; Park et al, 1991;
McDonald et al, 2003).
In addition, there are some potential morbidities associated with
pericardial sclerosis; most of the agents used as sclerosants
produce unpleasant adverse effects, such as fever and pain (Liu
et al, 1996). There is also concern about the complications of the
procedure, both in the short term, such as bleeding and infection,
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Figure 2 Effusion failure-free survival (EFFS) in effusion cytology-positive
patients. In the effusion cytology-positive patient subset, arm B favoured
EFFS. The hazard ratio was 0.69 (95% confidence interval: 0.39–1.21).
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Figure 3 Effusion failure-free survival (EFFS) in effusion cytology-negative
or -indeterminate patients. In the effusion cytology-negative or
-indeterminate patient subset, arm B favoured EFFS. The hazard ratio
was 0.39 (95% confidence interval: 0.12–1.21).
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Figure 4 Effusion failure-free survival (EFFS) and drainage method.
Patients with surgical drainage tended to have longer EFFS (median EFFS:
2.0 vs 1.1 month).
Table 3 Symptom palliation
Arm A (drainage alone) B (ipc BLM)
N eligible 42 37
% of those with improved or stable scores
a
Cough 60% 57%
Pain 50% 62%
Anorexia 55% 62%
Dyspnoea 62% 46%
Total 55% 51%
ipc BLM¼intrapericardial bleomycin instillation.
aThe scores at 1 month were
compared with those at enrolment.
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sand in the long term, such as constrictive pericarditis, as the
inflammatory response causes adhesion of the visceral and parietal
pericardium (Shepherd, 1997).
We undertook a randomised trial to evaluate the efficacy of
pericardial sclerosis following drainage as compared with drainage
alone. We chose BLM as the sclerosant agent for ipc instillation,
because of its low toxicity as compared with doxycycline, reported
from an earlier randomised trial (Liu et al, 1996). We included
only patients with non-small-cell lung cancer or chemotherapy-
treated small cell cancer to minimise the influence of systemic
chemotherapy after the protocol study (Vaitkus et al, 1994). We
randomised the patients after the pericardial drainage, as we
judged that obtaining informed consent before it, that is when the
patients suffer from symptoms of MPE, would be very difficult.
Therefore, we did not specify the indication for drainage and
enrolled cases after both emergent and elective drainage. We thus
focused on the prevention of MPE recurrence. We could not find
any comparable phase III trial on this participant, and no such trial
is registered in ClinicalTrial gov.
We found that ipc BLM instillation seemed to be effective at
preventing the recurrence of MPE. However, the benefit in the
primary end point, that is, EFFS at 2 months, was not significantly
different, which is a major drawback to make a definitive
conclusion. The therapeutic benefit, which could not be demon-
strated with our modestly sample-sized trial, therefore, might be
only a modest one. On the other hand, the benefit of ipc BLM
seemed to be unrelated to the drainage method. As expected, the
OS was poor in both arms and not significantly different.
Our study has several limitations. One is that without significant
survival prolongation and difference of symptom scores, modest
improvement of the EFFS might not represent true patient benefit.
We believe, however, that conductance of our trial itself would be
fully justified; given the severe symptoms of uncontrolled MPE and
the inconvenience of the drainage tube, survival without MPE
would be a worthwhile treatment goal.
The second limitation was that we limited the participants to
lung cancer patients, which makes it difficult to evaluate late
complications due to short OS. In patients with more chemother-
apy-sensitive tumours such as breast cancer or lymphoma, many
more patients may be expected to live for up to at least 1 year
longer. There would be greater concern about late pericardial or
cardiac complications, which we did observe in two of our own
cases. Even for lung cancer patients, advances in systemic therapy
may be expected to improve the outcome of those with even far-
advanced disease in the future, which would evidently modify the
risk/benefit of ipc BLM.
The third limitation of our study was that we did not control for
the method of primary pericardial drainage, and each institution
chose it in accordance with its daily practice. We do not believe
that our results were much biased by the drainage methods, as
each participating institution basically adhered to one method of
its choice, and the ipc BLM arm tended to favour EFFS in both
subgroups with surgical and non-surgical drainage. However,
control for the drainage method or indication (emergent vs
elective) for drainage might be necessary in future trials, as they
might well affect the patient outcomes. In fact, we did observe that,
although not a randomised comparison and thus it should be
interpreted with caution, patients who underwent surgical
drainage tended to have a better MPE control.
Recently, less invasive techniques for surgical treatment of
MPE have been described, such as percutaneous balloon
pericardiotomy (Ziskind et al, 1993; Wang et al, 2002), which
create a pleuro-pericardial communication and allow fluid
drainage into pleural space. It was reported to be effective and
safe, and may potentially obviate the need for surgical interven-
tion. However, it has yet to be compared with other drainage
methods and its role has not been established. No patient
underwent this procedure in our study.
One ancillary finding of our study was that two patients died of
major bleeding during surgical attempts at re-drainage for
recurrent MPE. Although it has rarely been reported in the
literature, partial adhesions could have led to injury to the cardiac
wall during the surgical procedure.
In this trial, we evaluated the safety and efficacy of pericardial
sclerosis with a ‘classic’ sclerosant agent of BLM. Future trial
designs would include one to compare BLM with another agent
with a different mode of action, such as intrapericardial instillation
of a platinum compound as ‘local chemotherapy’.
In conclusion, we found that pericardial sclerosis with ipc BLM
after drainage appears to be safe and effective, overall, in the
management of MPE in patients with lung cancer and should be a
valid therapeutic option in these patients. We could not, however,
demonstrate a statistical significance in the primary end point with
the modest sample size of 80. The therapeutic advantage might not
be large enough, and more trials are warranted.
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